Jagsonpal Pharmaceuticals Q2 FY27 results: net profit ₹12.29 crore

How did Jagsonpal Pharmaceuticals perform in Q2 FY27?

Jagsonpal Pharmaceuticals reported consolidated revenue of ₹96.37 crore, EBITDA of ₹16.90 crore and an EBITDA margin of 17.5% for Q2 FY27. The company reported profit before tax of ₹16.42 crore, tax of ₹4.13 crore and net profit of ₹12.29 crore, with basic EPS of 1.86. The standalone basis showed revenue of ₹81.38 crore and profit after tax of ₹12.59 crore.

Total consolidated expenses were ₹81.97 crore, including cost of materials of ₹4.68 crore, employee cost of ₹23.33 crore, finance costs of ₹0.29 crore, depreciation of ₹2.21 crore and other expenses of ₹15.18 crore. Other income was ₹2.25 crore and the quarter included an exceptional charge of ₹0.23 crore. The filing did not provide a previous-quarter or year-ago comparison for the consolidated results in the supplied data.

For the first half of FY27, consolidated revenue was ₹178.6 crore and total income was ₹183.69 crore. Profit before tax was ₹34.1 crore, profit after tax was ₹25.48 crore and EPS was 3.86. The standalone first-half figures were not given.

What do the balance sheet and cash flow show?

At 30 September 2026, consolidated total assets were ₹318.27 crore and total equity was ₹244.28 crore. Borrowings were ₹0.9 crore and cash was ₹19.13 crore. Inventories were ₹26.59 crore, trade receivables ₹37.5 crore and trade payables ₹26.83 crore. The previous balance-sheet date was not provided, so a comparison with the earlier balance sheet is not available.

H1 FY27 operating cash flow was ₹25.46 crore, investing cash flow was ₹45.5 crore and financing cash flow was a negative ₹61.96 crore. The filing and supplied data did not provide the year-earlier cash-flow comparison or a closing cash figure.

What did Jagsonpal Pharmaceuticals' management say?

Management reiterated its ambition of INR500 crores in revenue by FY28 from the current portfolio without further acquisitions. It expected Q3 FY27 consolidated revenue above INR100 crores and consolidated EBITDA margin above 22%, while noting that Q4 faces a seasonal drag. Management also expected Q3 organic growth above 1.5x the expected Indian pharmaceutical market growth.

Management said Aequitas and Group Pharma would expand hospital access and combined doctor reach to about 1,37,000. Aequitas procurement benefits were expected to emerge from Q4, but management identified the lower-margin mix as the key execution risk. The company also expects organic growth to exceed 1.5x IPM in Q3, although current growth still trails the market.

Management identified API price pressure, integration of two acquisitions completed within roughly 90 days, the NRx restriction on Equirex, packaging and usage innovation required for legacy Indocap, and the absence of manufacturing or API ownership as risks. It expected standalone gross margin to improve by 50-75 bps year-on-year through product mix and price increases, while consolidated gross margin was expected to remain near the Q2 level.

How did Jagsonpal Pharmaceuticals shares react?

Jagsonpal Pharmaceuticals’ results were announced after market on 28 October 2026. The stock was down 3.1% after 5 minutes, down 1.5% after 15 minutes and down 1.1% after 30 minutes from the price when the filing appeared. It closed the reaction day down 6.2% from the previous close and was down 9.0% from the pre-results close by the next day’s close.

Earlier results-day moves were positive 1.1% on 29 July 2026, positive 2.1% on 27 April 2026 and negative 1.4% on 21 January 2026. The stock had fallen 5.0% on 3 November 2025, risen 7.8% on 26 July 2025, fallen 7.1% on 6 May 2025, risen 9.0% on 22 January 2025 and recorded no movement on 23 October 2024.

How did other Pharmaceuticals companies do?

The Pharmaceuticals peer set included 61 companies that had filed for the quarter. The median peer revenue growth was 18.9%. Jagsonpal Pharmaceuticals’ revenue growth was lower than the peer median, and 39 peers reported higher profit, based on the supplied comparison of 55 peers for that measure.

The peer data did not provide separate counts of companies growing faster or slower than Jagsonpal Pharmaceuticals. Among the peers for which profit was compared, 39 reported higher profit.